Multi-panel assay of serum autoantibodies in colorectal cancer
- 24 April 2018
- journal article
- research article
- Published by Springer Science and Business Media LLC in International Journal of Clinical Oncology
- Vol. 23 (5), 917-923
- https://doi.org/10.1007/s10147-018-1278-3
Abstract
Although serum p53 autoantibodies (s-p53-Abs) are induced even in the early stages of colorectal cancer, their positive rate is only approximately 20%. Therefore, we assessed the possibility of using other serum autoantibodies to increase the positive rates for detecting colorectal cancer.Keywords
Funding Information
- Medical and Biological LAboratories
- JSPS KAKENHI Grant (JP26462029)
This publication has 19 references indexed in Scilit:
- Three-year monitoring of serum p53 antibody during chemotherapy and surgery for stage IV rectal cancerClinical Journal of Gastroenterology, 2016
- Prospective evaluation of 64 serum autoantibodies as biomarkers for early detection of colorectal cancer in a true screening settingOncotarget, 2016
- Clinical significance of serum autoantibodies against Ras-like GTPases, RalA, in patients with esophageal squamous cell carcinomaEsophagus, 2015
- NY-ESO-1 autoantibody as a tumor-specific biomarker for esophageal cancer: screening in 1969 patients with various cancersThe Esophagus, 2015
- Autoantibodies as Potential Biomarkers for the Early Detection of Esophageal Squamous Cell CarcinomaAmerican Journal Of Gastroenterology, 2014
- Usefulness of serum p53 antibody measurement in colorectal cancer: an examination of 1384 primary colorectal cancer patientsSurgery Today, 2013
- Investigation of the freely available easy-to-use software ‘EZR’ for medical statisticsBone Marrow Transplantation, 2012
- Reevaluation of serum p53 antibody as a tumor marker in colorectal cancer patientsSurgery Today, 2011
- Clinical validation of an autoantibody test for lung cancerAnnals Of Oncology, 2010
- p53 autoantibodies predict subsequent development of cancerInternational Journal of Cancer, 2004